David R. Valdecanas
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Cancer Immunotherapy and Biomarkers, Cancer, Hypoxia, and Metabolism, Immunotherapy and Immune Responses, DNA Repair Mechanisms
Most-Cited Works
- → PDL1 Regulation by p53 via miR-34(2015)664 cited
- → Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy(2016)265 cited
- → Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer(2014)192 cited
- → Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy(2005)152 cited
- → CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation(2004)149 cited
- → Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells(2018)91 cited
- → MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation(2011)83 cited
- → Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro(2011)75 cited
- → In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation(2015)72 cited
- → 130-nm Albumin–Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain(2007)67 cited